Open access peer-reviewed Edited Volume

Interferon - Immune Metabolism

Hridayesh Prakash

Amity University

Dr. Prakash's major research areas are immunotherapy of persistent respiratory infections and cancer. He is unraveling the therapeutic potential of macrophages against solid and established tumors and their potential involvement in various cancer-directed interventions like radio and immune therapies. He is a fellow of the Royal Society of Biology (London, UK), a member of the International Union of Immunological Society, and a life member of the Indian and German immunology societies.


NK Cells LAK Cells Dendritic Cells Macrophages ACE2 Receptor Latent Bacterial Infections Gut Microbiome Payer's Patches Immune Directed Interventions Tumor Immunotherapy Energy Metabolism Lipid Metabolism

Register your interest in contributing to this book

Collaborate with our community and contribute your knowledge.

About the book

The immune system is one of the plastic systems of the body and is heavily engaged in managing an equilibrium in all systems. Interferon (IFN) is the key soluble component of the immune system, a potent inducer of TNF and the interleukin network, and, by and large, sufficient to control various infections, cancer, and immune deficiencies.

A double-edged IFN signaling network largely dictates the plasticity in the immune system which can tune up and down the functioning of the immune system for orchestrating immunity against invaders and cancers while maintaining homeostasis. Apart from managing infections and cancer, the IFN system has the potential for managing a large variety of infectious diseases including COVID-19 where Type I IFN/Gamma IFN rheostat can limit the spread of the infection in the host while adjusting the host immunity in its favor.

Several recent studies have demonstrated the impact of IFN signaling on the immune-related metabolism for which underlying molecular/immune mechanisms are not clear. In view of this, the main aim of this book is to discuss interferon biology, chemistry, and physiological aspects which are important for the immune-related metabolism in the host.

The second aim of the book is to emphasize how IFN can assist various targeted interventions, harness their therapeutic potential and benefit the health sector. The book will discuss various aspects of how IFN controls the STAT 3 / HIF -1/2α / mTOR-based immune metabolic programming of target cells. Within this frame, the book would also focus on the plausible impact of GAS and/or IRES elements with miRNA / lncRNA components for controlling the immune-related metabolism of host cells.

The book particularly invites submissions from those authors who are working on the impact of the IFN system (Type I IFN –IRF 4/9 factors) in the evasion strategy of pathogens and/or tumors in the host.

Publishing process

Book initiated and editor appointed

Date completed: November 5th 2021

Applications to edit the book are assessed and a suitable editor is selected, at which point the process begins.

Chapter proposals submitted and reviewed

Deadline Extended: Open for Submissions

Potential authors submit chapter proposals ready for review by the academic editor and our publishing review team.

Approved chapters written in full and submitted

Deadline for full chapters: February 1st 2022

Once approved by the academic editor and publishing review team, chapters are written and submitted according to pre-agreed parameters

Full chapters peer reviewed

Review results due: April 22nd 2022

Full chapter manuscripts are screened for plagiarism and undergo a Main Editor Peer Review. Results are sent to authors within 30 days of submission, with suggestions for rounds of revisions.

Book compiled, published and promoted

Expected publication date: June 21st 2022

All chapters are copy-checked and typesetted before being published. IntechOpen regularly submits its books to major databases for evaluation and coverage, including the Clarivate Analytics Book Citation Index in the Web of ScienceTM Core Collection. Other discipline-specific databases are also targeted, such as Web of Science's BIOSIS Previews.

About the editor

Hridayesh Prakash

Amity University

Dr. Hridayesh Prakash is a fellow of the Royal Society of Biology, London. Currently, he is an associate professor at the Institute of Virology and Immunology, Amity University, NOIDA. He has expertise in innate immunity with a special interest in macrophage immunobiology, tumor immunology/immunotherapy, cell-based immunotherapies, pulmonary infection biology, and radiation biology. Dr. Prakash conducts research to exploit various immunotherapeutics for managing persistent bacterial and viral Infections and gastric cancer. He is unraveling the therapeutic potential of M1 effector macrophages against solid tumors. He is also studying various mechanisms that certain pathogens like Helicobacter pylori, Chlamydia, and Mycobacteria are exploiting for polarizing M1 effector macrophages towards the M2 phenotype during chronic and persistent infections. Under this major objective, he is now validating the therapeutic impact of M1 effector macrophages for the control of persistent infection-driven cancer (adenocarcinoma) progression. Dr. Prakash is also exploring the palliative potential of macrophages against autoimmunity and chronic inflammatory disorders like IBD, radio-pneumonitis, pulmonary fibrosis, and radiation syndrome.

View profile

Book chapters authored 1

Books edited 1

Introducing your Author Service Manager

Ms. Martina Ivancic

Ask a question

Book will be abstracted and indexed in